Literature DB >> 27272495

The utility of PET/CT with (68)Ga-DOTATOC in sarcoidosis: comparison with (67)Ga-scintigraphy.

Tomomi Nobashi1, Yuji Nakamoto2, Takeshi Kubo1, Takayoshi Ishimori1, Tomohiro Handa3, Kiminobu Tanizawa4, Kohei Sano1, Michiaki Mishima3, Kaori Togashi1.   

Abstract

OBJECTIVE: This study was designed to compare the clinical efficacy of (68)Ga-DOTA-Tyr-octreotide (DOTATOC)-positron emission tomography (PET)/computed tomography (CT) with that of conventional (67)Ga-scintigraphy (GS), and to correlate quantitative parameters on DOTATOC-PET/CT with clinical data, in patients with sarcoidosis.
METHODS: Twenty patients who were histologically and/or clinically diagnosed with sarcoidosis and underwent both DOTATOC-PET/CT and GS were analyzed in this study. The numbers of patients with positive findings for each organ were determined. The total numbers of involved nodal areas in the chest, as determined by DOTATOC-PET and gallium single-photon emission tomography (Ga-SPECT), were compared. The correlations between quantitative parameters on PET and clinical laboratory data were evaluated.
RESULTS: DOTATOC-PET/CT was positive in 19 patients, being negative in only one patient with chronic inactive sarcoidosis, whereas GS was positive in 17 patients. DOTATOC-PET/CT visualized more lesions in lymph nodes, uvea, and muscles than did Ga-scintigraphy and identified more involved areas than did GS-SPECT (p < 0.0001). Whole-body active lesion volume showed a significant, but moderate correlation with angiotensin-converting enzyme level (ρ = 0.64, p = 0.0044).
CONCLUSIONS: PET/CT with DOTATOC may be superior to conventional GS in detecting sarcoidosis lesions, especially in lymph nodes, uvea, and muscles. Volumetric parameters in DOTATOC-PET/CT may be helpful in estimating the activity of sarcoidosis.

Entities:  

Keywords:  DOTATOC-PET/CT; Ga-scintigraphy; Sarcoidosis; Somatostatin receptor scintigraphy

Mesh:

Substances:

Year:  2016        PMID: 27272495     DOI: 10.1007/s12149-016-1095-6

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  10 in total

1.  Advanced cardiovascular imaging for the evaluation of cardiac sarcoidosis.

Authors:  Paco E Bravo; Amitoj Singh; Marcelo F Di Carli; Ron Blankstein
Journal:  J Nucl Cardiol       Date:  2018-11-02       Impact factor: 5.952

Review 2.  The role of positron emission tomography in the assessment of cardiac sarcoidosis.

Authors:  Dario Genovesi; Matteo Bauckneht; Corinna Altini; Cristina Elena Popescu; Paola Ferro; Lavinia Monaco; Anna Borra; Cristina Ferrari; Federico Caobelli
Journal:  Br J Radiol       Date:  2019-06-05       Impact factor: 3.039

3.  Radiotracers to Address Unmet Clinical Needs in Cardiovascular Imaging, Part 2: Inflammation, Fibrosis, Thrombosis, Calcification, and Amyloidosis Imaging.

Authors:  John C Stendahl; Jennifer M Kwan; Darko Pucar; Mehran M Sadeghi
Journal:  J Nucl Med       Date:  2022-07       Impact factor: 11.082

Review 4.  Potential novel imaging targets of inflammation in cardiac sarcoidosis.

Authors:  Jakob Park; Bryan D Young; Edward J Miller
Journal:  J Nucl Cardiol       Date:  2021-11-03       Impact factor: 3.872

Review 5.  Prospective of 68Ga Radionuclide Contribution to the Development of Imaging Agents for Infection and Inflammation.

Authors:  Irina Velikyan
Journal:  Contrast Media Mol Imaging       Date:  2018-01-04       Impact factor: 3.161

6.  Somatostatin receptor based hybrid imaging in sarcoidosis.

Authors:  Riemer H J A Slart; Klaas-Pieter Koopmans; Peter Paul van Geel; Henk Kramer; Harry J M Groen; C Tji-Joong Gan; Niek H J Prakken; Andor W J M Glaudemans; George D Nossent
Journal:  Eur J Hybrid Imaging       Date:  2017-12-15

7.  Somatostatin receptor imaging by SPECT and PET in patients with chronic inflammatory disorders: a systematic review.

Authors:  Luz Kelly Anzola; Andor W J M Glaudemans; Rudi A J O Dierckx; F Andres Martinez; Sergio Moreno; Alberto Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-28       Impact factor: 9.236

Review 8.  Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors.

Authors:  Rasmus Helgebostad; Mona-Elisabeth Revheim; Kjersti Johnsrud; Kristine Amlie; Abass Alavi; James Patrick Connelly
Journal:  Diagnostics (Basel)       Date:  2022-02-18

9.  111In-Pentetreotide Uptake Due to COVID-19 Vaccination.

Authors:  Sho Koyasu; Yuji Nakamoto
Journal:  Clin Nucl Med       Date:  2022-03-01       Impact factor: 7.794

Review 10.  Advances in Diagnostic Imaging for Cardiac Sarcoidosis.

Authors:  Osamu Manabe; Noriko Oyama-Manabe; Tadao Aikawa; Satonori Tsuneta; Nagara Tamaki
Journal:  J Clin Med       Date:  2021-12-11       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.